1063 related articles for article (PubMed ID: 15947929)
1. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
[TBL] [Abstract][Full Text] [Related]
2. Prediction of active drug plasma concentrations achieved in cancer patients by pharmacodynamic biomarkers identified from the geo human colon carcinoma xenograft model.
Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Wong TW; Kramer RA; Wild R; Lee FY
Clin Cancer Res; 2005 Aug; 11(15):5558-65. PubMed ID: 16061873
[TBL] [Abstract][Full Text] [Related]
3. Relationship between plasma exposure of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite and antitumor response in mice bearing human colon carcinoma xenografts.
Zamboni WC; Jung LL; Egorin MJ; Hamburger DR; Joseph E; Jin R; Strychor S; Ramanathan RK; Eiseman JL
Clin Cancer Res; 2005 Jul; 11(13):4867-74. PubMed ID: 16000585
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
[TBL] [Abstract][Full Text] [Related]
5. Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose.
Kamath AV; Lu D; Gupta P; Jin D; Xiang H; Wong A; Leddy C; Crocker L; Schaefer G; Sliwkowski MX; Damico-Beyer LA
Cancer Chemother Pharmacol; 2012 Apr; 69(4):1063-9. PubMed ID: 22203367
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.
Ciardiello F; Bianco R; Damiano V; De Lorenzo S; Pepe S; De Placido S; Fan Z; Mendelsohn J; Bianco AR; Tortora G
Clin Cancer Res; 1999 Apr; 5(4):909-16. PubMed ID: 10213228
[TBL] [Abstract][Full Text] [Related]
7. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
8. Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.
Damiano V; Caputo R; Bianco R; D'Armiento FP; Leonardi A; De Placido S; Bianco AR; Agrawal S; Ciardiello F; Tortora G
Clin Cancer Res; 2006 Jan; 12(2):577-83. PubMed ID: 16428503
[TBL] [Abstract][Full Text] [Related]
9. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics of DT-IgG, a dual-targeting antibody against VEGF-EGFR, in tumor xenografted mice.
Hurwitz SJ; Zhang H; Yun S; Batuwangala TD; Steward M; Holmes SD; Rycroft D; Pan L; Tighiouart M; Shin HJ; Koenig L; Wang Y; Chen ZG; Shin DM
Cancer Chemother Pharmacol; 2012 Mar; 69(3):577-90. PubMed ID: 21913035
[TBL] [Abstract][Full Text] [Related]
11. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy.
Tonra JR; Deevi DS; Corcoran E; Li H; Wang S; Carrick FE; Hicklin DJ
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2197-207. PubMed ID: 16609035
[TBL] [Abstract][Full Text] [Related]
12. In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR.
Balin-Gauthier D; Delord JP; Rochaix P; Mallard V; Thomas F; Hennebelle I; Bugat R; Canal P; Allal C
Cancer Chemother Pharmacol; 2006 Jun; 57(6):709-18. PubMed ID: 16320055
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
Ciardiello F; Bianco R; Damiano V; Fontanini G; Caputo R; Pomatico G; De Placido S; Bianco AR; Mendelsohn J; Tortora G
Clin Cancer Res; 2000 Sep; 6(9):3739-47. PubMed ID: 10999768
[TBL] [Abstract][Full Text] [Related]
14. Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma.
Park SJ; Kim MJ; Kim YK; Kim SM; Park JY; Myoung H
Cancer Lett; 2010 Jun; 292(1):54-63. PubMed ID: 19959278
[TBL] [Abstract][Full Text] [Related]
15. Preclinical pharmacokinetics and safety of Sym004: a synergistic antibody mixture directed against epidermal growth factor receptor.
Skartved NJ; Jacobsen HJ; Pedersen MW; Jensen PF; Sen JW; Jørgensen TK; Hey A; Kragh M
Clin Cancer Res; 2011 Sep; 17(18):5962-72. PubMed ID: 21825041
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effect of FP3 in combination with cetuximab on patient-derived tumor tissue xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases.
Dong X; Jin K; Hu X; Du F; Lan H; Han N; Ma Z; Xie B; Cui B; Teng L; Cao F
Int J Mol Med; 2012 Jul; 30(1):126-32. PubMed ID: 22505231
[TBL] [Abstract][Full Text] [Related]
17. Preclinical pharmacokinetics of MFGR1877A, a human monoclonal antibody to FGFR3, and prediction of its efficacious clinical dose for the treatment of t(4;14)-positive multiple myeloma.
Kamath AV; Lu D; Gupta P; Jin D; Xin Y; Brady A; Stephan JP; Li H; Tien J; Qing J; Damico-Beyer LA
Cancer Chemother Pharmacol; 2012 Apr; 69(4):1071-8. PubMed ID: 22203368
[TBL] [Abstract][Full Text] [Related]
18. Dose-dependent increases in circulating TGF-alpha and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent.
Mutsaers AJ; Francia G; Man S; Lee CR; Ebos JM; Wu Y; Witte L; Berry S; Moore M; Kerbel RS
Clin Cancer Res; 2009 Apr; 15(7):2397-405. PubMed ID: 19276250
[TBL] [Abstract][Full Text] [Related]
19. Death receptor 5 agonistic antibody PRO95780: preclinical pharmacokinetics and concentration-effect relationship support clinical dose and regimen selection.
Xiang H; Reyes AE; Eppler S; Kelley S; Damico-Beyer LA
Cancer Chemother Pharmacol; 2013 Aug; 72(2):405-15. PubMed ID: 23771513
[TBL] [Abstract][Full Text] [Related]
20. Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.
Thomas SM; Ogagan MJ; Freilino ML; Strychor S; Walsh DR; Gooding WE; Grandis JR; Zamboni WC
Mol Pharmacol; 2008 Mar; 73(3):627-38. PubMed ID: 18025070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]